#### Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Amphastar Pharmaceuticals, Inc. Form 4 September 02, 2016

September (	02, 2010	6										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL				
Check this box       UNITED STATES SECURITIES AND EXCHANGE COMMISS         Washington, D.C. 20549         Check this box         if no longer         subject to         Section 16.         Form 4 or         Form 5         obligations         may continue.         See Instruction         See Instruction						OMMISSION	OMB Number:	3235-0287				
						IN BENEFICIAL OWNERSHIP OF URITIES f the Securities Exchange Act of 1934 Iolding Company Act of 1935 or Secti				Expires: January 3 200 Estimated average burden hours per response 0		
1(b).						_						
(Print or Type	Response	es)										
1. Name and Address of Reporting Person <u>*</u> Lee Howard				2. issuer i kane and i tener of i trading					5. Relationship of Reporting Person(s) to Issuer			
				Amphastar Pharmaceuticals, Inc. [AMPH]					(Check all applicable)			
(Last) (First) (Middle) C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET				(Month/Dav/Year) –					_X_Director10% Owner Officer (give titleOther (specify below) below)			
				Filed(Month/Day/Year) A					5. Individual or Joint/Group Filing(Check Applicable Line) .X_ Form filed by One Reporting Person			
RANCHO CUCAMO	NGA, C	CA 91730						i	Form filed by Mo Person	ore than One Rep	oorting	
(City)	(St	ate)	(Zip)	Tab	ole I - Non-	Derivative	Secur	rities Acqu	ired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)		Transaction Date 2A. Deemed onth/Day/Year) Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired (A) Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common	00/01	0010			Code V		(D)	Price		D		
Stock	09/01/	2016			М	10,381	А	\$ 15.23 \$	124.908	D		
Common Stock	09/01/	/2016			S	10,381	D	φ 18.7763 (1)	114,527	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form

#### Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

# displays a currently valid OMB control number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	5. Transaction Date 3A. Deemed Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. 5. Number of Transactio-Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		cisable and ate Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (.
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 15.23	09/01/2016		М	10,381	(2)	10/03/2016	Common Stock	10,381	

### **Reporting Owners**

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
Lee Howard C/O AMPHASTAR PHARMACEUTICAI 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	LS, INC.	X					
Signatures							
/s/ Ken Stupak, by power of attorney	09/02/201	6					

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.70
 (1) to \$18.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

(2) Shares subject to the option are fully vested and immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.